Search results for "OBESE SUBJECTS"

showing 10 items of 11 documents

Maintenance of weight loss after obesity treatment: is continuous support necessary?

2002

Abstract Objective: This study examined outcome differences of 109 obese subjects, who participated in a 10-week cognitive-behavioral inpatient treatment followed by either a weight maintenance program or a follow-up period without professional support. Methods: Self-rated weight loss, eating behaviors, and general psychopathology were assessed several months before treatment, when subjects were admitted, at discharge, and at the 6-, 12-, and 18-month follow-ups. Structured interviews for mental disorders and eating pathology were conducted additionally. Results: The mean weight of the sample at baseline was 127 kg. Weight loss of the total sample amounted to 8.0 kg (6.3%) and was completel…

Adultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentExperimental and Cognitive PsychologySeverity of Illness IndexBody Mass IndexWeight lossSurveys and QuestionnairesWeight maintenanceWeight LossmedicineHumansObesityPsychiatric Status Rating ScalesCognitive Behavioral TherapyMental DisordersProfessional supportmedicine.diseaseObesityPsychiatry and Mental healthClinical PsychologyGeneral psychopathologyStructured interviewPhysical therapyCognitive therapyFemaleObese subjectsmedicine.symptomEnergy IntakePsychologyFollow-Up StudiesBehaviour Research and Therapy
researchProduct

Micro-albuminuria in obese subjects: relationship among body fat distribution, blood pressure and left ventricular structure and function.

1998

OBJECTIVE: To evaluate the relationships among micro-albuminuria, blood pressure and measurements of left ventricular structure and function in centrally and peripherally obese subjects compared with members of a lean control group. METHODS: Centrally obese subjects were subdivided according to whether they had levels of micro-albuminuria higher than 30 mg/24 h (micro-albuminuric group) or lower than or equal to 30 mg/24 h (normo-albuminuric group). For all the subjects we measured heart rate, casual mean blood pressure (MBP), 24 h MBP, total cholesterol level, high-density lipoprotein cholesterol, lipoprotein (a) level, fasting immunoreactive insulin level, plasma renin activity, plasma al…

Settore MED/09 - Medicina Internaobese subjects: body fat distributionblood pressureMicro-albuminurialeft ventricularSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato Cardiovascolarebody fat distribution; blood pressure; left ventricular [Micro-albuminuria; obese subjects]
researchProduct

Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

2020

Background Obesity is associated with high cardiovascular risk. Postprandial lipidaemia has been associated with cardiovascular disease risk. Our aim was to identify whether anthropometric parameters, insulin resistance (IR) and/or fasting plasma triglycerides may determine postprandial changes in lipoprotein concentrations in abdominal and morbid obese subjects. Methods We have studied 20 non-diabetic, normolipidaemic subjects with abdominal obesity, 20 morbid obese subjects and 20 healthy individuals, that have similar age and gender. In all of them a standardised oral fat load test (OFLT) with unsaturated fat was performed. Results During the OFLT, the postprandial triglycerides response…

medicine.medical_specialtyWaist030204 cardiovascular system & hematologyGastroenterologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansInsulin030212 general & internal medicineTriglyceridesAbdominal obesitybusiness.industryUnsaturated fatGeneral MedicinePostprandial Periodmedicine.diseaseObesityObesity MorbidPostprandialchemistryObese subjectsInsulin Resistancemedicine.symptombusinessLipoproteinInternational Journal of Clinical Practice
researchProduct

Fat Distribution and Adipose Products in Polycystic Ovary Syndrome

2007

Because adipose tissue is a complex endocrine organ that secretes many substances with profound effects on metabolism and the cardiovascular (CV) system, most obese subjects have an increased CV risk. However, 20% of obese subjects are metabolically healthy, and many studies suggest that fat distribution, in particular abdominal fat excess, is the most important factor that determines a secretion of adipose products that may increase CV risk.

medicine.medical_specialtybusiness.industryHyperandrogenismAdipose tissueFat distributionmedicine.diseasePolycystic ovaryEndocrinologyInternal medicinemedicineAbdominal fatEndocrine systemSecretionObese subjectsbusiness
researchProduct

Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects

2003

Fifty-six young central obese patients were investigated to evaluate relationships between soluble E-selectin (sE-S), angiotensin-converting enzyme (ACE) gene polymorphism, left ventricular function and structure, and carotid morphology by determination of sE-S and ACE genotypes. Our results indicated that central obese subjects with concomitant higher levels of sE-S and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease.

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internaangiotensin-converting-enzyme cardiovascular damageGenotypeArteriosclerosisEndocrinology Diabetes and MetabolismBlood PressureDiseasecentral obese subjectsPeptidyl-Dipeptidase ABody Mass Indexcirculating E-selectin genotype; angiotensin-converting-enzyme cardiovascular damage; central obese subjectsEndocrinologyRisk FactorsInternal medicineGenotypeE-selectinmedicineHumansInsulinObesityAllelesbiologyVentricular functionHemodynamicsHeartAngiotensin-converting enzymeGlucose Tolerance TestSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheIsoenzymesCarotid ArteriesEndocrinologyCardiovascular DiseasesEchocardiographyConcomitantbiology.proteinRegression AnalysisFemaleObese subjectsGene polymorphismE-Selectincirculating E-selectin genotypeMetabolism
researchProduct

Liking for fat is associated with sociodemographic, psychological, lifestyle and health characteristics

2014

Sensory liking influences dietary behaviour, but little is known about specifically associated individual profiles. The aim of the present study was to investigate the associations between liking for fat-and-salt and fat-and-sweet sensations and sociodemographic, economic, psychological, lifestyle and health characteristics in a large sample. Individual characteristics and liking scores were collected by a questionnaire among 37 181 French adults. Liking scores were constructed using a validated preference questionnaire. Multinomial logistic regression models were used to assess the associations between liking levels and individual characteristics. In both sexes, subjects belonging to low-l…

AdultMaleRisklikingAdolescent[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionhabitude alimentairesociodemographic factorsMedicine (miscellaneous)enquêteHyperphagiapsychological factorsBody Mass IndexCohort StudiesFood PreferencesYoung AdultSurveys and Questionnaires[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyfatSensationHumansObesitysantéLife StyleAgedMultinomial logistic regressionAged 80 and overInternetNutrition and DieteticssociologieCognitionMiddle AgedDietary FatssociodémographiePreferenceLarge sampleobésitéSocioeconomic FactorsFemaleObese subjectsFrancedietary determinantsPsychology[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesClinical psychology
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

A low reported energy intake is associated with metabolic syndrome.

2009

Background and aims: Metabolic syndrome (MS) may be associated with the presence of an energy sparing metabolism that predisposes to the excess accumulation of body fat. This study examined the relationship between reported energy intake and obesity in individuals with and without MS. Methods and results: Ninety consecutive non-diabetic obese subjects were divided into two groups based on the presence (MS+: n= 50) or absence (MS-: n= 40) of metabolic syndrome. The study design was cross-sectional. The three-day food record method was used to assess the subjects' usual energy intake and the Diet Readiness Test (DRT) was also administered. Compared to the MS- group, the MS+ group had a signif…

AdultBlood GlucoseMalemedicine.medical_specialtyMetabolic syndrome energy intake obesityEndocrinology Diabetes and MetabolismBlood PressureBody weightFat massBody Mass IndexEndocrinologyHeart RateInternal medicinemedicineHumansInsulinObesityMetabolic SyndromeInsulin bloodbusiness.industryBody Weightmedicine.diseaseObesityFood recordEndocrinologyBody CompositionLinear ModelsObese subjectsFemaleBasal MetabolismMetabolic syndromebusinessEnergy IntakeBody mass index
researchProduct

Levels of serum retinol-binding protein 4 before and after non-surgical periodontal treatment in lean and obese subjects: An interventional study

2018

AimWe aimed to evaluate serum RBP4 levels before and after periodontal therapy in lean and obese subjects with chronic periodontitis (CP) in order to determine its possible association with periodontitis. Materials and MethodsThis is an interventional study for which a total of 112 lean and 119 obese subjects were recruited. Patients with CP were evaluated before and after three months of non-surgical periodontal treatment. Periodontal, anthropometric, biochemical parameters and serum levels of TNF-, IL-6, hs-CRP and RBP4 were assessed. ResultsSerum RBP4 levels were associated with an increased probability of periodontitis (OR=1.60; 95% CI: 1.02-2.50), showing patients with CP to have highe…

AdultMalenon-surgical periodontal treatment0301 basic medicineobesityPeriodontal treatmentmedicine.medical_specialtySerum retinolGastroenterologyBody Mass IndexYoung Adult03 medical and health sciences0302 clinical medicineThinnessInternal medicinemedicineHumansObesityperiodontitisPeriodontitisAnalysis of Variancebusiness.industryRBP4030206 dentistryMiddle AgedAnthropometrymedicine.diseaseChronic periodontitisObesity030104 developmental biologyChronic PeriodontitisPeriodonticsFemaleObese subjectsPeriodontal IndexbusinessRetinol-Binding Proteins Plasmaperiodontal diseasesJournal of Clinical Periodontology
researchProduct

Emerging approaches for the treatment of hypertriglyceridemia.

2013

Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjec…

PharmacologyHypertriglyceridemiamedicine.medical_specialtyAtherogenic dyslipidemiabusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseBioinformaticsFish consumptionClinical PracticeEndocrinologyIncreased riskPostprandialInternal medicinecardiovascular diseases triglycerides hypertriglyceridemia triglyceride-lowering agentsmedicineIncreased triglyceridesHumansPharmacology (medical)Obese subjectsbusinessLife StyleHypolipidemic AgentsExpert opinion on pharmacotherapy
researchProduct